TROPHIT1—a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients

Background: Colorectal cancer (CRC) ranks among the most common malignancies worldwide. Response rates to standard-of-care (SOC) treatment drop sharply beyond the second treatment line. Trophoblast cell surface antigen-2 (TROP2) acts in a plethora of cellular processes and ectopic expression is dete...

Full description

Bibliographic Details

Published in:	ESMO Gastrointestinal Oncology
Main Authors:	B.C. Köhler, G.M. Haag, L. Le Cornet, P. Hoffmeister-Wittmann, M. Schmidt, A. Manjunath, N. Vaquero-Siguero, M. Jenzer, M. Gimmel, A. Stahler, A. Stein, M. Reichert, S. Kasper, M. Bitzer, D. Jäger, C. Springfeld, T.F. Weber, S. Fröhling, K. Steindorf, A. Trumpp, R.F. Schlenk, R. Jackstadt
Format:	Article
Language:	English
Published:	Elsevier 2025-03-01
Subjects:	TROP2 clinical trial resistance patient-reported outcome reverse translation
Online Access:	http://www.sciencedirect.com/science/article/pii/S2949819824000797